Veraxa Biotech Expands Heidelberg Facilities to Advance Cancer Therapy Pipeline

VERAXA Biotech (NASDAQ: VRXA), a developer of novel cancer therapies, announced an expansion of its laboratory space at its research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The move supports planned growth of the company’s R&D team, installation of new equipment, and completion of infrastructure needed to advance its drug development pipeline.

The expansion aligns with VERAXA’s efforts to progress its proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline centers on its BiTAC platform, which includes BiTAC-TCE and BiTAC-ADC candidates designed to enable tumor-restricted activation of cancer therapies through complementary precursor molecules.

By increasing its laboratory footprint, VERAXA aims to accelerate the development of next-generation antibody-based therapeutics. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a renowned institution for life science research. VERAXA’s approach combines transformative technologies with quality-by-design principles to advance bispecific T cell engagers, bispecific ADCs, and other innovative formats.

The expansion in Heidelberg is a strategic step to strengthen the company’s R&D capabilities as it prepares to move candidates into clinical testing. VERAXA’s BiTAC platform is designed to improve the safety and efficacy of cancer therapies by restricting activation to tumor sites, potentially reducing off-target effects common in traditional treatments.

For more information on VERAXA’s pipeline and updates, visit the company’s newsroom at https://ibn.fm/VRXA. The full press release is available at https://ibn.fm/n3t6U.

Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ. These include factors outlined in VERAXA’s SEC filings, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update these statements unless required by law.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Veraxa Biotech Expands Heidelberg Facilities to Advance Cancer Therapy Pipeline.

The post Veraxa Biotech Expands Heidelberg Facilities to Advance Cancer Therapy Pipeline appeared first on citybuzz.